IP Verse

A Rapamycin Derivative For Treating Lung Cancer

Patent No. EP3143995 (titled "A Rapamycin Derivative For Treating Lung Cancer") was filed by Novartis on Feb 18, 2002. The application was issued on Jan 15, 2025.

Patent Summary

A compound, 40-O-(2-hydroxyethyl)-rapamycin, for treating solid tumors, particularly lung cancer, by inhibiting angiogenesis and tumor growth. The compound, a derivative of the macrolide antibiotic rapamycin, selectively targets endothelial cells and suppresses their proliferation, particularly in response to vascular endothelial growth factor (VEGF). It exhibits antitumor activity in preclinical models, including human lung and epidermoid tumor xenografts, and shows potential for combination therapy with conventional anticancer agents.

Patent Family

Patent Family

Patent Oppositions (7)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
ACCORD HEALTHCARESep 5, 2019PLOUGMANN VINGTOFT
GENERICS UKSep 5, 2019ELKINGTON AND FIFE
STADA ARZNEIMITTELSep 5, 2019HAMM & WITTKOPP
ZENTIVA KSSep 3, 2019BIRD & BIRD
TEVA PHARMACEUTICALSAug 30, 2019GREINER
SYNTHONAug 27, 2019BENNEKER
ETHYPHARMJun 12, 2019LLR

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3143995

NOVARTIS
Application Number
EP16186041A
Filing Date
Feb 18, 2002
Status
Patent Maintained As Amended
Dec 13, 2024
Publication Date
Jan 15, 2025
External Links
Slate, Register , Google Patents